<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="108">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04337996</url>
  </required_header>
  <id_info>
    <org_study_id>RIPH_2020_6</org_study_id>
    <nct_id>NCT04337996</nct_id>
  </id_info>
  <brief_title>Dynamic Evaluation of COVID-19 Diagnostic Tests</brief_title>
  <acronym>TRODVID-19</acronym>
  <official_title>Dynamic Evaluation of COVID-19 Diagnostic Tests</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tourcoing Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tourcoing Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Rapid antigenic tests are not yet used in real life. Their contribution in the diagnostic&#xD;
      strategy based on the gold standard including anamnesis, thoracic CT and PCR has not been&#xD;
      evaluated.&#xD;
&#xD;
      We propose to compare to the Gold-Standard defined above, the combination of an SARS-Cov-2&#xD;
      antigen, anamnesis and thoracic CT for the diagnosis of COVID-19 infection.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an interventional study comparing gold standard anamnesis, thoracic CT and PCR versus&#xD;
      SARS-Cov-2 antigen, anamnesis and thoracic CT for the diagnosis of COVID-19 infection.&#xD;
&#xD;
      Patients will be sampled for the tests at Day 1 and then monitored for symptoms and clinical&#xD;
      data and additional test at Day 21.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 13, 2020</start_date>
  <completion_date type="Actual">January 13, 2021</completion_date>
  <primary_completion_date type="Actual">January 13, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Comparison of the proportion of patients classified as COVID-19 positive according to the 2 strategies</measure>
    <time_frame>day 1</time_frame>
    <description>Comparison of the Gold-Standard PCR, anamnesis, thoracic CT scan versus SARS-Cov-2 antigen, anamnesis and thoracic CT scan</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Positive or negative Covid-19 test</measure>
    <time_frame>day 1</time_frame>
    <description>Number of diagnoses invalidated by the antigen + CT scan alone without the contribution of PCR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Positive or negative character of the antibodies test</measure>
    <time_frame>day 1</time_frame>
    <description>Comparison of the proportion of patients with positive serology for SARS-Cov2 to the proportion of patients who were classified as COVID-19</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Positive or negative character of the antibodies test</measure>
    <time_frame>day 21</time_frame>
    <description>Comparison of the proportion of patients with positive serology for SARS-Cov2 to the proportion of patients who were classified as COVID-19 at the time of hospitalization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biological parameters</measure>
    <time_frame>day 1</time_frame>
    <description>Evolution of biological parameters as a function of time IgM IgA and IgG</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biological parameters</measure>
    <time_frame>Day 21</time_frame>
    <description>Evolution of biological parameters as a function of time IgM IgA and IgG</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>medical-economic comparison</measure>
    <time_frame>day 1</time_frame>
    <description>medical-economic comparison of the first-line use of the antigenic test</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>experimental arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>These are patients whose diagnosis of SARS-Cov-2 infection was made on the Gold-Standard: combined history/clinical examination, PCR and CT scan and requiring hospitalization at Tourcoing Hospital.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>COVID-19 diagnostic test</intervention_name>
    <description>COVID-19 diagnostic tests performed at day 1 (antigen in blood serum, SARS-Cov2 PCR, antibodies in blood serum) COVID-19 diagnostic test performed at day 21 (antibodies in blood serum)</description>
    <arm_group_label>experimental arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Symptomatic patient with confirmed Gold-Standard SARS-CoV-2 (COVID-19) infection&#xD;
&#xD;
          -  Presenting at least one criterion for hospitalization:&#xD;
&#xD;
               -  Respiratory failure and oxygenation&#xD;
&#xD;
               -  Circulatory failure (systolic BP &lt; 90 mmHg)&#xD;
&#xD;
               -  Neurological failure (confusion, drowsiness, altered consciousness)&#xD;
&#xD;
               -  Polypathological terrain and co-morbidities (chronic respiratory failure, heart&#xD;
                  failure or cardiovascular pathology, renal failure, diabetes, immunosuppression,&#xD;
                  obesity, cirrhosis)&#xD;
&#xD;
          -  Eligible for different sampling methods&#xD;
&#xD;
          -  Beneficiary of a social insurance scheme or entitled person&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Gold Standard not in favour of SARS-Cov-2 infection (COVID 19)&#xD;
&#xD;
          -  Minor patient&#xD;
&#xD;
          -  Refusal to participate&#xD;
&#xD;
          -  Patient under guardianship&#xD;
&#xD;
          -  Patient under guardianship&#xD;
&#xD;
          -  Pregnant or breastfeeding woman&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pierre PATOZ, PharmD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CH Tourcoing</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Barthelemy LAFONDESMURS, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CH Tourcoing</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CH Tourcoing</name>
      <address>
        <city>Tourcoing</city>
        <zip>59208</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>April 1, 2020</study_first_submitted>
  <study_first_submitted_qc>April 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 8, 2020</study_first_posted>
  <last_update_submitted>January 25, 2021</last_update_submitted>
  <last_update_submitted_qc>January 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

